Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma

被引：8

作者：

Igarashi, T ^{[1
]}

Tobe, T ^{[1
]}

Kuramochi, H ^{[1
]}

Akakura, K ^{[1
]}

Ichikawa, T ^{[1
]}

Hamano, S ^{[1
]}

Suzuki, N ^{[1
]}

Furuya, Y ^{[1
]}

Ito, H ^{[1
]}

机构：

[1] Chiba Univ, Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2001年 / 31卷 / 01期

关键词：

immunosuppressive acidic protein; renal cell carcinoma; metastatic; survival rates; cutoff level;

D O I：

10.1093/jjco/hye004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Estimation of survival probability of individual patients with metastatic renal cell carcinoma was difficult owing to diverse prognostic factors. We analyzed serum immunosuppressive acidic protein (IAP) levels and the cutoff value, then tested its validity for assessing patients' prognoses. Methods: Serum IAP was measured longitudinally in 84 patients with metastatic disease. Before therapy, cutoff levels of IAP were tested every 20 mug/ml between 600 and 1200 mug/ml. The prognostic importance of IAP and its cutoff level was estimated. Results: The cutoff level of IAP was set at 800 mug/ml for 40 patients who had metastatic disease with the primary tumor in situ and for 44 patients with recurrent disease. IAP was found to be a significant prognostic factor for both patient groups. Conclusions: Serum IAP is an important prognostic factor for patients with metastatic renal cell carcinoma. Stratification of patients according to prognosis is feasible using the cutoff level.

引用

页码：13 / 17

页数：5

共 26 条

[1]

Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO

[2]

2-R

[3]

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA TREATED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA [J].

CANOBBIO, L ;

RUBAGOTTI, A ;

MIGLIETTA, L ;

CANNATA, D ;

CUROTTO, A ;

AMOROSO, D ;

BOCCARDO, F .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (12) :753-756

[4]

Citterio G, 1997, EUR UROL, V31, P286

[5]

INTERFERON-ALPHA AND SURVIVAL IN RENAL-CELL CANCER [J].

FOSSA, S ;

JONES, M ;

JOHNSON, P ;

JOFFE, J ;

HOLDENER, E ;

ELSON, P ;

RITCHIE, A ;

SELBY, P .

BRITISH JOURNAL OF UROLOGY, 1995, 76 (03) :286-290

[6]

Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma [J].

Fujikawa, K ;

Matsui, Y ;

Oka, H ;

Fukuzawa, S ;

Takeuchi, H .

JOURNAL OF UROLOGY, 1999, 162 (06) :1934-1937

[7]

IGARASHI T, 1991, EUR UROL, V19, P332

[8]

Ito H, 1999, SCAND J GASTROENTERO, V34, P1139

[9]

Katoh R, 1997, ANTICANCER RES, V17, P3787

[10]

Resection of metastatic renal cell carcinoma [J].

Kavolius, JP ;

Mastorakos, DP ;

Pavlovich, C ;

Russo, P ;

Burt, ME ;

Brady, MS .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2261-2266

← 1 2 3 →